BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.…
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
BioNTech (NASDAQ: BNTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7,807 employees.
The shares were at 80.96 USD on 20 November 2026, down 27.5% over 52 weeks. Its 52-week range is 79.52 USD to 124.00 USD: the price is 34.7% below the high and 1.8% above the low.
Its market capitalisation is 20.07B USD.
BioNTech reports return on equity of -5.9%, an operating margin of -55.4% and revenue down 15.1% year over year.
It holds more cash than debt, a net cash position of 13.34B EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 112.14 USD is 38.5% above the current price. The next earnings report is expected on 2 March 2027.